The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a significant substantial reduction in body size and improve metabolic func